Effect of oral pre-meal administration of betaglucans on glycaemic control and variability in subjects with type 1 diabetes

Research output: Contribution to journalArticle

Standard

Effect of oral pre-meal administration of betaglucans on glycaemic control and variability in subjects with type 1 diabetes. / Frid, Anders; Tura, Andrea; Pacini, Giovanni; Ridderstråle, Martin.

In: Nutrients, Vol. 9, No. 9, 1004, 12.09.2017.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Effect of oral pre-meal administration of betaglucans on glycaemic control and variability in subjects with type 1 diabetes

AU - Frid, Anders

AU - Tura, Andrea

AU - Pacini, Giovanni

AU - Ridderstråle, Martin

PY - 2017/9/12

Y1 - 2017/9/12

N2 - We conducted a double-blind placebo-controlled crossover pilot study to investigate the effect of oat betaglucans (β-glucan) on glycaemic control and variability in adults with type 1 diabetes (T1D; n = 14). Stomacol® tablets (1.53 g of β-glucan) or placebo (Plac) were administered three times daily before meals for two weeks. Glucose levels were monitored during the second week by continuous glucose monitoring (CGM). There was an increase in basic measures of glycaemic control (maximal glucose value 341 ± 15 vs. 378 ± 13 mg/dL for Plac and β-glucan, p = 0.004), and average daily risk range (62 ± 5 vs. 79 ± 4 mg/dL for Plac and β-glucan, p = 0.003) favouring Plac over β-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures. Basic measures of glucose variability were also slightly increased during β-glucan treatment, with no difference in more complex measures. However, glycaemic variability increased between the first and last two CGM days on Plac, but remained unchanged on β-glucan. In conclusion, in this pilot study we were unable to demonstrate a general positive effect of β-glucan before meals on glucose control or variability in T1D.

AB - We conducted a double-blind placebo-controlled crossover pilot study to investigate the effect of oat betaglucans (β-glucan) on glycaemic control and variability in adults with type 1 diabetes (T1D; n = 14). Stomacol® tablets (1.53 g of β-glucan) or placebo (Plac) were administered three times daily before meals for two weeks. Glucose levels were monitored during the second week by continuous glucose monitoring (CGM). There was an increase in basic measures of glycaemic control (maximal glucose value 341 ± 15 vs. 378 ± 13 mg/dL for Plac and β-glucan, p = 0.004), and average daily risk range (62 ± 5 vs. 79 ± 4 mg/dL for Plac and β-glucan, p = 0.003) favouring Plac over β-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures. Basic measures of glucose variability were also slightly increased during β-glucan treatment, with no difference in more complex measures. However, glycaemic variability increased between the first and last two CGM days on Plac, but remained unchanged on β-glucan. In conclusion, in this pilot study we were unable to demonstrate a general positive effect of β-glucan before meals on glucose control or variability in T1D.

KW - Betaglucan

KW - Diabetes

KW - Glucose control

KW - Glucose variability

KW - Viscous fiber

U2 - 10.3390/nu9091004

DO - 10.3390/nu9091004

M3 - Article

VL - 9

JO - Nutrients

T2 - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 9

M1 - 1004

ER -